Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Y. Ohe

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- Or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Journal of Thoracic Oncology

Respiratory Medicine

English

MA 17.06 Safety Data From Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined With TRT for Locally Advanced Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.17-06 Salvage Surgery After Chemotherapy and/or Radiotherapy Including SBRT and Proton: Consecutive Analysis of 46 Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy After Nivolumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.15-004 Underrepresentation of Elderly Patients With ED-SCLC as Clinical Trial Candidates (JCOG1201/TORG1528)

Journal of Thoracic Oncology

Respiratory Medicine

English

P080 Efficacy and Safety of Docetaxel Plus Ramucirumab: A Consecutive Analysis of 68 Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

Journal of Thoracic Oncology

Respiratory Medicine

English

OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs

Journal of Thoracic Oncology

Respiratory Medicine

English

TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-mutant Lung Cancer

Annals of Oncology

English